Spotlight On... Gates Foundation backs Affinivax's Prevnar 13 rival; FDA rejects Vertex's latest Kalydeco app; and much more...

Cambridge, MA's Affinivax secured another $2.5 million in funding from the Bill and Melinda Gates Foundation to support its work on a pneumococcal vaccine that can best Pfizer's top-selling Prevnar 13. The raise follows a $4 million check from the Gates Foundation at Affinivax's launch in 2014, and the company said it's moving toward clinical trials with its candidate. More

@FierceBiotech: FierceBiotech Radio on Gilead's wide-open future, biotech's long winter and Sanofi's ongoing makeover. More/Subscribe | Follow @FierceBiotech

@JohnCFierce: Hey, we got a picture to add to our  apology piece. From a Roth party. Check it out. Story | Follow @JohnCFierce

> The FDA rejected Vertex Pharmaceuticals' ($VRTX) attempt to get its cystic fibrosis therapy Kalydeco approved for a larger patient population. News

> Biotech's recent downturn may have battered companies' share prices, but the IPO successes of yesteryear are still sitting on a lot of cash, Atlas Venture's Bruce Booth points out. Post

> Massachusetts biotech Silk Therapeutics raised $6 million in a Series A2 round, bringing its total funding to about $10.3 million as it develops silk-based skincare products. Item

Medical Device News

@FierceMedDev: IYCMI yesterday: FDA OKs use of Medtronic's CoreValve TAVR on end-stage renal disease patients. Article | Follow @FierceMedDev

@EmilyWFierce: Valeant, Turing slammed for price hikes during congressional hearing. More from FiercePharma | Follow @EmilyWFierce

> Scientists call for development of quick Zika tests as epidemic rages on. Story

> Cellnovo partners with TypeZero in major NIH-backed artificial pancreas trial in Type 1 diabetics. Article

Pharma News

@FiercePharma: Scientists pinpoint contributions pets can make to human medicine. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Teva is adding 20 jobs at UK plant, but only after cutting 80 as it looks for different skills. Article | Follow @EricPFierce

@CarlyHFierce: Blockbuster new launches coming from Intercept, Gilead and Merck: Reuters. Article | Follow @CarlyHFierce

> FDA shoots down Vertex's latest bid for Kalydeco expansion. Story

> AstraZeneca CEO still interested in M&A but he is getting very picky. Report

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.